Now Fresh Good Gravy(TM) from Petcurean Named “Dog Bone Broth Product of the Year” by Pet Innovation Annual Awards Program Recognizes Companies, Services And Products Within The Rapidly Expanding Pet Industry That Exemplify Excellence & Innovation GlobeNewswire August 07, 2025 LOS ANGELES, Aug. 07, 2025 (GLOBE NEWSWIRE) — The 2025 Pet Innovation Awards today announced […]
(NASDAQ:MBX), Topline results for the Phase 2 Avail(TM) trial of canvuparatide in hypoparathyroidism on track for Q3 2025 Imapextide (MBX 1416) Phase 2a trial initiation in patients with post-bariatric hypoglycemia anticipated in Q3 2025 MBX 4291 Phase 1 trial initiation in obesity anticipated in Q3 2025 $224.9 million in cash, cash equivalents and marketable securities
MetLife Pet Insurance Named “Pet Insurance of the Year” In 2025 Pet Innovation Awards Annual Awards Program Recognizes Companies, Services and Products Within the Rapidly Expanding Pet Industry That Exemplify Excellence & Innovation GlobeNewswire August 07, 2025 LOS ANGELES, Aug. 07, 2025 (GLOBE NEWSWIRE) — The 2025 Pet Innovation Awards today announced that MetLife Pet
Lithium South Development Corporation(the “Company” or “Lithium South”) (TSX-V: LIS) (OTCQB: LISMF) (Frankfurt: OGPQ) is providing an update to it's news release of July 30, 2025 regarding the sale of the Hombre Muerto North Lithium Project property package (the “Transaction”) to POSCO Argentina SAU, which is the 100-per-cent-owned Argentine subsidiary of POSCO Holdings Inc. (“POSCO”).
WASHINGTON, Aug. 07, 2025 (GLOBE NEWSWIRE) — Labrynth, a regulatory intelligence company dedicated to streamlining permitting approvals across government and industry, today announced the launch of the Red Tape Index. This new index provides the first comprehensive, data-driven benchmark designed to track and compare how efficiently U.S. states process building permits, zoning changes, and related
(NASDAQ:OSS), Second quarter of 2025 consolidated gross margin increased over 600 basis points year-over-year to 31.3%, on consolidated revenue of $14.1 million OSS segment gross margin of 41.3%, on OSS segment revenue of $5.8 million Year-to-date OSS segment bookings of $25.4 million, supports outlook for accelerating revenue growth and improving profitability for the second half
(NasdaqGM:URGN), ZUSDURI(TM) (mitomycin) for intravesical solution now available as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) JELMYTO(R) achieved net product sales of $24.2 million in Q2 2025, compared with $21.8 million in Q2 2024, representing 11% year-over-year growth $161.6 million in cash, cash equivalents and
(NASDAQ:ICCC), PORTLAND, Maine, Aug. 07, 2025 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30,
(Other OTC:AONC),(OTC US:AONC), BETHESDA, Md., Aug. 07, 2025 (GLOBE NEWSWIRE) — American Oncology Network (AON), one of the nation's fastest-growing networks of community-based oncology practices, and its partner practice, The Center for Cancer and Blood Disorders (CCBD), are pleased to welcome Board-certified medical oncologists Garrett Diltz, MD, and Shreya Desai, MD, to the care team.
(CNSX:TRUE.CN),(OTC US:TREIF),(OTCQB:TREIF),(Boerse Frankfurt – Freiverkehr:939), 2024 marked the worst year on record for ER closures in Ontario, with 1 in 5 hospitals experiencing unplanned shutdowns, especially in rural areas. Ontario's family physician workforce is aging, with 15% of patients attached to doctors nearing retirement and 2.5 million Ontarians lacking a family doctor as of 2023.